Before the advent of tyrosine kinase inhibitors, the median survival time for<unk>  patients had been about 3–5 years from time of diagnosis. With the use of tyrosine kinase inhibitors, survival rates have improved dramatically. A 2006 follow-up of 553 patients using imatinib (Gleevec) found an overall survival rate of 89% after five years. A 2011 followup of 832 patients using imatinib who achieved a stable cytogenetic response found an overall survival rate of 95.2% after 8 years, which is similar to the rate in the general population. Fewer than 1% of patients died because of leukemia progression.
Chronic myelogenous leukemia
Acute myeloid leukemia
Chronic neutrophilic leukemia
Myeloid leukemia
Chronic lymphocytic leukemia
Acute monocytic leukemia
Prolymphocytic leukemia
Lymphoid leukemia